GLP1R and thyroid gland carcinoma: A Scandinavian cohort study looking at 145,410 patients using GLP1‐agonists also found no significant increased risk of thyroid cancer over a mean follow‐up of 3.9 years (HR = 0.90, 95% CI 0.58 to 1.38) [25].